Arcutis Biotherapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-06
- Employees
- 296
- Market Cap
- $1.2B
- Website
- http://www.arcutis.com
- Introduction
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in ...
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 432
- Registration Number
- NCT05028582
- Locations
- 🇺🇸
Arcutis Biotherapeutics Clinical Site 13, Arlington, Texas, United States
🇺🇸Arcutis Biotherapeutics Clinical Site 31, North Miami Beach, Florida, United States
🇺🇸Arcutis Biotherapeutics Clinical Site 72, Santa Ana, California, United States
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 457
- Registration Number
- NCT04973228
- Locations
- 🇺🇸
Arcutis Biotherapeutics Clinical Site 65, Sanford, Florida, United States
🇺🇸Arcutis Biotherapeutics Clinical Site 28, Rockville, Maryland, United States
🇺🇸Arcutis Biotherapeutics Clinical Site 42, Coral Gables, Florida, United States
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
- Conditions
- Interventions
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 652
- Registration Number
- NCT04845620
- Locations
- 🇺🇸
Arcutis Clinical Site 16, Reno, Nevada, United States
🇺🇸Arcutis Clinical Site 55, Lebanon, New Hampshire, United States
🇺🇸Arcutis Clinical Site 31, Hershey, Pennsylvania, United States
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT04811131
- Locations
- 🇺🇸
Arcutis Site 123, San Diego, California, United States
🇺🇸Arcutis Clinical Site 163, Pflugerville, Texas, United States
🇺🇸Arcutis Site 167, Coral Gables, Florida, United States
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 1220
- Registration Number
- NCT04804605
- Locations
- 🇺🇸
Arcutis Clinical Site 69, Beverly Hills, California, United States
🇺🇸Arcutis Clinical Site 93, Clarksville, Indiana, United States
🇺🇸Arcutis Clinical Site 88, Clarkston, Michigan, United States
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
- Conditions
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 683
- Registration Number
- NCT04773600
- Locations
- 🇺🇸
Arcutis Clinical Site 34, Rockville, Maryland, United States
🇺🇸Arcutis Clinical Site 36, San Diego, California, United States
🇺🇸Arcutis Clinical Site 41, Miami, Florida, United States
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 654
- Registration Number
- NCT04773587
- Locations
- 🇺🇸
Arcutis Clinical Site 10, New Brighton, Minnesota, United States
🇺🇸Arcutis Clinical Site 62, Thousand Oaks, California, United States
🇺🇸Arcutis Clinical Site 57, Montgomery, Alabama, United States
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04746911
- Locations
- 🇺🇸
Arcutis Clinical Site 608, Los Angeles, California, United States
🇨🇦Arcutis Clinical Site 621, Toronto, Ontario, Canada
🇺🇸Arcutis Clinical Site 610, Boca Raton, Florida, United States
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04655313
- Locations
- 🇺🇸
Arcutis Clinical Site 506, Arlington, Texas, United States
🇺🇸Arcutis Site 518, Los Angeles, California, United States
🇺🇸Arcutis Clinical Site 509, Fountain Valley, California, United States
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Arcutis Biotherapeutics, Inc.
- Target Recruit Count
- 408
- Registration Number
- NCT04445987
- Locations
- 🇺🇸
Arcutis Biotherapeutics Clinical Site 27, Pittsburgh, Pennsylvania, United States
🇺🇸Arcutis Biotherapeutics Clinical Site 10, Rolling Meadows, Illinois, United States
🇺🇸Arcutis Biotherapeutics Clinical Site 51, Encino, California, United States